NOTE 8 – SUBSEQUENT EVENTS	6 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]
NOTE 8 – SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS In accordance with ASC Topic 855-10, the Company analyzed its operations subsequent to September 30, 2023 to the date these financial statements were issued, and determined it does not have any material subsequent events to disclose in these financial statements, except as noted below. On October 16, 2023, TPR Global Limited, Equipped 4 Holdings Limited and Phytotherapeutix Holdings Ltd converted a total of $2.35m USD of debt in Alterola Biotech Inc. (the “Company”) into common shares at a price of $0.004 per share.

NOTE 8 – SUBSEQUENT EVENTS

6 Months Ended

Sep. 30, 2023

NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company analyzed its operations subsequent to September 30, 2023 to the date these financial statements were issued, and determined it does not have any material subsequent events to disclose in these financial statements, except as noted below.

On October 16, 2023, TPR Global Limited, Equipped 4 Holdings Limited and Phytotherapeutix Holdings Ltd converted a total of $2.35m USD of debt in Alterola Biotech Inc. (the “Company”) into common shares at a price of $0.004 per share.

ALTEROLA BIOTECH INC. 10-Q